I think you're absolutely right. My assertion that "achieving 'herd immunity' is the overarching aim of the strategy" is wrong.
Once Groups 1-9 are vaccinated, that'll be 18-20M 'done - I've suggested possible dates elsewhere (?mid April). Aiui the programme will continue, presumably at the same pace, for under 50s, with some juggling to the 'top' of sections of the working population whose employment renders them at greater risk, and others eg teachers and the police.
I suspect that our leaders are steering well clear of the 'herd immunity' phrase after the bad press it got in March (and rightly so).
Achieving country-wide herd immunity depends on, inter alia, on the extent to which vaccinated (+ 14 days) but then infected individuals can transmit the infection (qv).
And we don't know this (because the trials didn't have it as an objective to test), but I hope we will by April. I hope that Israel's early experience will help the world, here.
Same for vaccinating under 18s. I assume there's work ongoing to determine the efficacy and safety of the vaccine(s) in the yoof with a target for results by (say) midsummer.
There will be some decision challenges ahead, in particular when it'd be right for UK to reduce the domestic vaccination rate and divert some supply to other countries: eg Eire, Gibraltar and less prosperous Commonwealth Family countries. But such issues will be opportunity challenges, not wicked problems.
JCVI: "JCVI has considered a number of different vaccination strategies, including those targeting transmission and those targeted at providing direct protection to persons most at risk.
"In order to interrupt transmission, mathematical modelling indicates that we would need to vaccinate a large proportion of the population with a vaccine which is highly effective at preventing infection (transmission). At the start of the vaccination programme, good evidence on the effects of vaccination on transmission will not be available . . ."
"Given the current epidemiological situation in the UK, the best option for preventing morbidity and mortality in the initial phase of the programme is to directly protect persons most at risk of morbidity and mortality."